- Merck’s investigational RSV antibody, Clesrovimab (MK-1654), significantly reduced RSV disease and hospitalization in preterm and full-term infants.
Thu Oct 17 23:01:14 -0000 2024 UTC– Merck & Co., Inc. released news about their Clesrovimab (MK-1654) monoclonal antibody reducing RSV disease and hospitalizations in infants,
Respiratory Syncytial Virus RSV
RSV is the leading cause of hospitalization for infants, and is a seasonal infection. Like the flu, it is a worldwide burden in infants and older adults. It may lead to respiratory conditions like bronchiolitis and pneumonia. It is estimated to cause 101,000 deaths a year worldwide in children under five.
RSV season usually starts in the fall and peaks in the winter in most regions of the United States and Europe.
Results from MK-1654-004 met all endpoints, with consistent results through both the 5-month and 6-month periods. The incidence of adverse events (AEs) and serious AEs were comparable between the clesrovimab and placebo groups, and there were no treatment or RSV-related deaths during the study, Merck & Co said.